Evotec SE (NASDAQ: EVO) is a Healthcare company in the Drug Manufacturers - Specialty & Generic industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | - | EPS (ttm) | -0.65 | Insider Own | 0.14% | Shs Outstand | 355.24M | Perf Week | -7.51% |
| Market Cap | 568.38M | Forward P/E | - | EPS next Y | -0.18 | Insider Trans | - | Shs Float | 336.88M | Perf Month | -19.19% |
| Enterprise Value | 579.38M | PEG | - | EPS next Q | -0.35 | Inst Own | - | Short Float | 0.03% | Perf Quarter | -37.50% |
| Income | -233.00M | P/S | 0.68 | EPS this Y | -15.20% | Inst Trans | - | Short Ratio | 1.69 | Perf Half Y | -34.69% |
| Sales | 840.00M | P/B | 0.75 | EPS next Y | 75.31% | ROA | -12.52% | Short Interest | 91.44K | Perf YTD | -48.05% |
| Book/sh | 2.14 | P/C | 1.07 | EPS next 5Y | - | ROE | -26.46% | 52W High | 4.27 -62.53% | Perf Year | -56.04% |
| Cash/sh | 1.49 | P/FCF | - | EPS past 3/5Y | - | ROIC | -9.58% | 52W Low | 1.57 1.91% | Perf 3Y | -86.46% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | 2.63% 8.38% | Gross Margin | 10.49% | Volatility | 4.32% 2.44% | Perf 5Y | -93.88% |
| Dividend TTM | - | EV/Sales | 0.69 | EPS Y/Y TTM | -7.29% | Oper. Margin | -17.68% | ATR (14) | 0.07 | Perf 10Y | -37.25% |
| Dividend Ex-Date | Jan 11, 2019 | Quick Ratio | 2.21 | Sales Y/Y TTM | -2.55% | Profit Margin | -27.47% | RSI (14) | 28.87 | Recom | 2.43 |
| Dividend Gr. 3/5Y | -49.75% - | Current Ratio | 2.33 | EPS Q/Q | -15.21% | SMA20 | -11.65% | Beta | 1.95 | Target Price | 3.00 |
| Payout | 0.00% | Debt/Eq | 0.55 | Sales Q/Q | -12.37% | SMA50 | -17.53% | Rel Volume | 17.53 | Prev Close | 1.67 |
| Employees | 4,553 | LT Debt/Eq | 0.42 | Earnings | Nov 05 | SMA200 | -42.26% | Avg Volume | 78.61K | Price | 1.60 |
| IPO Date | Feb 05, 2004 | Option/Short | No / Yes | EPS/Sales Surpr. | -327.78% -0.06% | Net Debt/EBITDA | -4.58 | Volume | 1,378,041 | Change | -4.19% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jul-15-26 | Reiterated | Macquarie | $2.00 | |
| Jul-15-26 | Reiterated | HC Wainwright & Co. | Buy | $4.00 |
| Aug-14-25 | Reiterated | HC Wainwright & Co. | Buy | |
| Aug-15-24 | Reiterated | HC Wainwright & Co. | Buy | |
| Apr-25-24 | Reiterated | HC Wainwright & Co. | Buy | |
| Jun-23-23 | Upgrade | Morgan Stanley | Equal Weight → Overweight | |
| Jun-16-23 | Downgrade | B of A Securities | Buy → Neutral | |
| Jun-08-23 | Upgrade | Citigroup | Neutral → Buy | |
| Apr-04-23 | Upgrade | Morgan Stanley | Underweight → Equal Weight | |
| Dec-09-22 | Reiterated | HC Wainwright & Co. | Buy |
Evotec SE operates globally as a dedicated partner, specializing in the discovery and advancement of new pharmaceutical products for the biotechnology and pharmaceutical sectors. Its comprehensive research and development initiatives encompass a broad spectrum of medical areas, such as metabolic disorders (including diabetes and its complications), fibrosis, infectious conditions, central nervous system (CNS) diseases, oncology, pain management, inflammatory ailments, immunological dysfunctions, rare diseases, respiratory conditions, and women's health. The company maintains strategic alliances and collaborations with numerous prominent organizations, including Bayer AG, Lilly, Chinook Therapeutics, Novo Nordisk A/S, Galapagos, Pfizer Inc., CONBA Pharmaceutical Co., Ltd., Bristol Myers Squibb Company, Zhejiang JingXin Pharmaceutical Co., Ltd, Kazia Therapeutics, Apeiron Biologics, and Takeda Pharmaceuticals. Established in 1993, the company was formerly known as Evotec AG, changing its name to Evotec SE in April 2019. Its corporate headquarters are located in Hamburg, Germany.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 840 | 854 | 862 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 753 | 784 | 738 | — | — | — | — | — | — | |
| Gross Profit | 87 | 71 | 124 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 198 | 139 | 204 | — | — | — | — | — | — | |
| Research and Development | 45 | 84 | 55 | — | — | — | — | — | — | |
| Other Operating Expense | -6 | 0 | 19 | — | — | — | — | — | — | |
| Operating Income | -150 | -153 | -154 | — | — | — | — | — | — | |
| Interest Expense | 14 | 16 | 13 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -55 | 29 | -43 | — | — | — | — | — | — | |
| Net Income Before Taxes | -218 | -139 | -210 | — | — | — | — | — | — | |
| Income Taxes | 15 | -27 | 2 | — | — | — | — | — | — | |
| Consolidated Net Income | -233 | -112 | -212 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | -233 | -112 | -212 | — | — | — | — | — | — | |
| Net Income | -233 | -112 | -212 | — | — | — | — | — | — | |
| EPS (Recurring) | -0.65 | -0.32 | -0.61 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -0.65 | -0.32 | -0.61 | — | — | — | — | — | — | |
| EPS (Diluted) | -0.65 | -0.32 | -0.61 | — | — | — | — | — | — | |
| EBITDA | -101 | -16 | -87 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 0.68 | 1.28 | 1.70 | — | — | — | — | — | — | |
| Gross Margin | 10.36 | 8.31 | 14.39 | — | — | — | — | — | — | |
| Operating Margin | -17.86 | -17.92 | -17.87 | — | — | — | — | — | — | |
| Net Margin | -27.74 | -13.11 | -24.59 | — | — | — | — | — | — | |
| Shares Outstanding | 356 | 355 | 353 | — | — | — | — | — | — | |
| Market Capitalization | 570 | 1,093 | 1,468 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| BANK OF AMERICA CORP /DE/ | 10% Owner | Oct 18 '11 | Buy | 12.81 | 392 | 5,023 | 392 | Oct 25 |
| BANK OF AMERICA CORP /DE/ | 10% Owner | Oct 18 '11 | Sale | 12.75 | 392 | 4,999 | 0 | Oct 25 |